[Corneal collagen crosslinking with riboflavin in keratoconus]
Piatigorsky N, García Martí S, Colaci C, Lazo E, Alfie V, Ciapponi A, Bardach A, Augustovski F, Alcaraz A, Pichon-Riviere A
Record ID 32018004412
Spanish
Original Title:
Crosslinking del colágeno corneal con riboflavina en queratocono
Authors' recommendations:
Moderate‐quality evidence shows that corneal collagen cross‐linking with riboflavin in patients with progressive keratoconus probably results in a significant net benefit when compared with the use of rigid lenses or corneal ring implantation since it stabilizes disease progression and is associated to a mild visual acuity improvement after 12 months.
Moderate‐quality evidence shows that, in young patients with progressive keratoconus, crosslinking results in a clinically significant improvement of corneal power after 5 years versus the use of rigid lenses or corneal ring implantation.
In the United States, the public sector does not cover this technology, but the private health funders Aetna, Anthem and Cigna do cover it. The United Kingdom national health system offers coverage for this procedure. Other health funders consulted do not mention this technology. Coverage of corneal collagen crosslinking with riboflavin is not mentioned by the health funders consulted in Latin America, including Argentina.
No health technology assessments carried out in Argentina on the use of crosslinking in keratoconus have been found. Economic evaluations carried out in the United States and Canada determined that crosslinking with riboflavin was cost effective when compared with rigid lenses.
Details
Project Status:
Completed
Year Published:
2022
URL for published report:
https://www.iecs.org.ar/publicacion/?id=22188
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Keratoconus
- Corneal Cross-Linking
- Cross-Linking Reagents
- Riboflavin
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.